Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.42 |
| ▸ | ASPH | Q12797 | 10/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 9/20 | 0.42 |
| ▸ | RIOX2 | Q8IUF8 | 7/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849394 | 0.87 | DHODH (0.36) | KDM4EMAPK1L3MBTL1CA1CA2 | |
| SCHEMBL24848943 | 0.84 | DHODH (0.34) | KDM4EMAPK1CA1CA2DHODH | |
| SCHEMBL24848964 | 0.84 | DHODH (0.36) | MAPK1CA1CA2DHODHCA9 | |
| SCHEMBL24849669 | 0.84 | DHODH (0.36) | KDM4EMAPK1CA1CA2DHODH | |
| SCHEMBL29425395 | 0.83 | KDM4E (0.43) | KDM4EASPHKDM8RIOX2MAPK1 | |
| SCHEMBL23673984 | 0.83 | KDM4E (0.43) | KDM4EASPHKDM8RIOX2MAPK1 | |
| SCHEMBL24849644 | 0.76 | NUDT1 (0.33) | CA1CA2DHODHMAP2K1 | |
| SCHEMBL24195914 | 0.73 | LMNA (0.38) | KDM4EMAPK1CA1CA2CA9 | |
| SCHEMBL24196100 | 0.73 | KEAP1 (0.36) | KDM4EMAPK1CA1CA2CA9 | |
| SCHEMBL24196097 | 0.70 | MAP2K1 (0.37) | KDM4ECA1CA2CA9MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | KDM4E 597/4885ASPH 2545/4885KDM8 802/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | KDM4E 1507/4885ASPH 3738/4885KDM8 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.